سعر اليمبوسيس 2.5 مجم 30 قرص مغلف 2022

Elimbosis 2.5 mg 30 f.c. tabs.: apixaban film-coated tablets by Debeiky / Zeta Pharm.

• Reduction of the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation.Population: AdultsDailyMed (U.S. NLM)
• Prophylaxis of deep vein thrombosis following hip or knee replacement surgery.Population: AdultsDailyMed (U.S. NLM)
• Treatment of deep vein thrombosis and pulmonary embolism.Population: AdultsDailyMed (U.S. NLM)

• The most common adverse reactions in adults are related to bleeding.International label, same formulation · DailyMed (U.S. NLM)

• Active pathological bleeding; severe hypersensitivity reaction to apixaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. NLM)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant if stopped for reasons other than pathological bleeding or completion of therapy.International label, same formulation · DailyMed (U.S. NLM)
• Boxed warning: epidural or spinal haematoma (possibly permanent paralysis) with neuraxial anaesthesia or spinal puncture; do not remove indwelling catheters earlier than 24 hours after the last dose and wait at least 5 hours after removal before the next dose.International label, same formulation · DailyMed (U.S. NLM)
• Apixaban increases the risk of serious, potentially fatal bleeding, increased by antiplatelets, other anticoagulants, heparin, thrombolytics, SSRIs, SNRIs and NSAIDs.International label, same formulation · DailyMed (U.S. NLM)

• Combined P-gp and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir)Increase apixaban exposure: reduce 5 mg/10 mg twice-daily doses by 50%; avoid in patients on 2.5 mg twice daily. Clarithromycin: no dose adjustment needed per PK data.DailyMed (U.S. NLM)
• Combined P-gp and strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St John's wort)Decrease apixaban exposure and increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. NLM)
• Anticoagulants, antiplatelet agents, fibrinolytics, heparin, aspirin, chronic NSAIDsIncrease the risk of bleeding.DailyMed (U.S. NLM)

• Limited data in pregnant women are insufficient to inform drug-associated risks; treatment may increase the risk of bleeding during pregnancy and delivery. No adverse developmental effects in animal studies.International label, same formulation · DailyMed (U.S. NLM)
• No human data; apixaban accumulates in rat milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. NLM)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and prothrombinase activity, decreasing thrombin generation; no direct effect on platelet aggregation (US label).